Publications - Eccogene

Publications

11.18.2024
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ECC0509, an SSAO Inhibitor for MASH, in a Phase 1 trial.

AASLD The Liver Meeting 2024.
11.18.2024
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ECC4703, a Highly Selective Liver Targeting Thyroid Hormone Receptor-beta (THR-b) Full Agonist for MASH in a Phase 1 Trial.

AASLD The Liver Meeting 2024.
11.05.2024
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.

Diabetes, Obesity and Metabolism
11.04.2024
AZD5004/ECC5004, a Small Molecule GLP-1 Receptor Agonist May Be Administered Once Daily Under Fed/Fasted Conditions.

ObesityWeek® 2024.
11.04.2024
Safety, Tolerability and Pharmacokinetics of AZD/ECC5004, an Oral Small Molecule GLP-1 Receptor Agonist.

ObesityWeek® 2024.
6.22.2022
ECC4703, a full thyroid hormone receptor β (THRβ) agonist, demonstrates excellent selectivity and liver targeting properties and improvement of plasma lipids, NAFLD activity score and fibrosis in NASH animal model.

The International Congress on Obesity (ICO) 2022.
11.14.2021
ECC0509, a novel peripherally distributed and selective semicarbazidesensitive amino oxidase (SSAO) inhibitor for NASH treatment.

American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021.